Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer

This prospective, multicenter clinical study evaluates the efficacy and safety of NALIRIFOX in combination with Stereotactic Body Radiation Therapy (SBRT) for patients with locally advanced unresectable pancreatic cancer. The primary endpoint is progression-free survival (PFS), with secondary endpoints including objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety assessment. The study involves two cohorts: Cohort 1 (early SBRT after 1 cycle of NALIRIFOX) and Cohort 2 (late SBRT after 6-8 cycles of NALIRIFOX). A total of 42 participants are expected to b

Trial Details

NCT ID
NCT07173387
Phase
PHASE2
Sponsor
Shandong Cancer Hospital and Institute
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • NALIRIFOX (liposomal irinotecan-based chemotherapy).
  • Stereotactic Body Radiation Therapy (SBRT).
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Adults aged 18-75 years, both male and female. Histologically or cytologically confirmed locally advanced unresectable pancreatic cancer.
  • No prior chemotherapy or radiatiotherapy for pancreatic cancer. ECOG performance status of 0-1.
  • Adequate organ function as defined by the following criteria:
  • Absolute neutrophil count (ANC) ≥ 1,500/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 times the upper limit of normal (U…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →